Pfizer, Inc. (PFE) Shares Sold by Traynor Capital Management Inc.

Traynor Capital Management Inc. decreased its position in Pfizer, Inc. (NYSE:PFE) by 2.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 31,350 shares of the biopharmaceutical company’s stock after selling 647 shares during the period. Traynor Capital Management Inc.’s holdings in Pfizer were worth $1,035,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Northstar Group Inc. boosted its stake in Pfizer by 0.4% in the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 35 shares during the period. River Wealth Advisors LLC boosted its stake in Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 55 shares during the period. Meridian Wealth Management LLC boosted its stake in Pfizer by 0.5% in the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 57 shares during the period. Stone House Investment Management LLC boosted its stake in Pfizer by 0.9% in the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares during the period. Finally, Telemus Capital LLC boosted its stake in Pfizer by 0.5% in the 2nd quarter. Telemus Capital LLC now owns 17,888 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 92 shares during the period. 69.36% of the stock is owned by institutional investors.

WARNING: “Pfizer, Inc. (PFE) Shares Sold by Traynor Capital Management Inc.” was published by Markets Daily and is the property of of Markets Daily. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/11/13/pfizer-inc-pfe-shares-sold-by-traynor-capital-management-inc.html.

In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ian C. Read sold 197,168 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the transaction, the chief executive officer now directly owns 580,318 shares in the company, valued at $19,730,812. The disclosure for this sale can be found here. Over the last three months, insiders sold 374,621 shares of company stock worth $12,796,098. Insiders own 0.06% of the company’s stock.

A number of brokerages recently weighed in on PFE. BMO Capital Markets reaffirmed a “buy” rating and issued a $39.00 target price on shares of Pfizer in a research note on Friday. J P Morgan Chase & Co set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Jefferies Group LLC set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, November 1st. Finally, UBS AG set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $38.48.

Shares of Pfizer, Inc. (PFE) opened at $35.18 on Monday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market cap of $209,697.67, a PE ratio of 14.07, a PEG ratio of 2.49 and a beta of 1.01. Pfizer, Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 EPS. analysts predict that Pfizer, Inc. will post 2.59 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.64%. Pfizer’s dividend payout ratio is currently 79.01%.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply